Medicamen Biotech touches the roof on getting ANVISA Brazil nod for tablets

12 Dec 2011 Evaluate

Medicamen Biotech is currently locked at its upper circuit limit of Rs. 16.15, up by 0.75 points or 4.87% from its previous closing of Rs. 15.40 on the BSE.

The scrip opened at Rs. 15.90 and has touched a high and low of Rs. 16.15 and Rs. 15.90 respectively. So far 19287 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 38.10 on 17-Oct-2011 and a 52 week low of Rs. 14.05 on 23-Nov-2011.

Last one week high and low of the scrip stood at Rs. 19.70 and Rs. 15.40 respectively. The current market cap of the company is Rs. 12.15 crore.

The promoters holding in the company stood at 34.84% while Non-Institutions held 65.16%.

Medicamen Biotech has received an ANVISA Brazil approval for Non Beta Lactum solid tablets and coated tablets manufactured at its plant situated at Bhiwadi in Rajasthan vide resolution 5397 No RE of December 02, 2011, officially published in the gazzatte on December 05, 2011 valid for 2 years.

Medicamen Biotech manufactures pharmaceutical formulations for the Indian and overseas markets. Its product range consists of antibiotics, anti-fungicides, anti-diabetics, anti-tuberculosis, tranquillisers, laxatives, anti-asthmatics, and anti-depressants.

Medicamen Biotech Share Price

381.90 -8.35 (-2.14%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×